Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019.

Clark, Kristina E N; Nevin, William D; Mahungu, Tabitha; Lachmann, Helen; Singh, Animesh

Clark, Kristina E N; Nevin, William D; Mahungu, Tabitha; Lachmann, Helen; Singh, Animesh.

Afiliação

Clark KEN; Department for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom.
Nevin WD; Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.
Mahungu T; Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.
Lachmann H; UK National Amyloidosis Centre, University College London, London, United Kingdom.
Singh A; Department of Rheumatology, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.

Clin Infect Dis ; 73(9): e3110-e3112, 2021 11 02.

Article em En | MEDLINE | ID: mdl-32985664

ABSTRACT

ABSTRACT

The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.

Assuntos

COVID-19; Linfo-Histiocitose Hemofagocítica; Humanos; Linfo-Histiocitose Hemofagocítica/diagnóstico; Fatores de Risco; SARS-CoV-2

Palavras-chave

HLH; COVID-19; HScore; cytokine storm

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfo-Histiocitose Hemofagocítica / COVID-19 Tipo de estudo: Diagnostic_studies / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google